Clinical Trial Update: Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating circulating tumor DNA to guide changes in standard chemotherapy for metastatic HER2-negative breast cancer and metastatic trip…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Carcinoma
• Triple-negative Breast Carcinoma

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Metastatic HER2-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma | Phase 2 | Status: RECRUITING